For patients diagnosed with locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA), the first line of therapy often represents the most meaningful opportunity to ...
Less than six months after debuting as the first drug that can target a rare tumor type in patients with non-small cell lung cancer (NSCLC), Boehringer Ingelheim’s Hernexeos has quickly widened its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results